Malignant adrenal neoplasms

Problems in General Surgery

Volumn 20, Issue 3, 2003, Pages 92-102

  Al Fehaily, Maha ^a   Duh, Quan Yang ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 125; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; CATECHOLAMINE; CYCLOPHOSPHAMIDE; DACARBAZINE; KETOCONAZOLE; METIROSINE; METYRAPONE; MITOTANE; OCTREOTIDE; VINCRISTINE;

ADRENAL CORTEX ADENOMA; ADRENAL CORTEX CARCINOMA; ADRENAL CORTEX INSUFFICIENCY; ADRENALECTOMY; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; CATECHOLAMINE BLOOD LEVEL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; HORMONAL REGULATION; HUMAN; LAPAROSCOPIC SURGERY; MALIGNANT TRANSFORMATION; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROGNOSIS;

EID: 0141620226     PISSN: 07398328     EISSN: None     Source Type: Journal    
DOI: 10.1097/00013452-200309000-00011     Document Type: Article

References (98)

1. Hutter AM Jr, Kayhoe DE. Adrenal cortical carcinoma. Results of treatment with o,p′DDD in 138 patients. Am J Med 1966;41(4):581-592.
2. Hutter AM Jr, Kayhoe DE. Adrenal cortical carcinoma. Clinical features of 138 patients. Am J Med 1966;41(4):572-580.
3. Kopf D, Goretzki PE, Lehnert H. Clinical management of malignant adrenal tumors. J Cancer Res Clin Oncol 2001;127(3):143-155.
4. Howe JR, Norton JA, Wells SA Jr. Prevalence of pheochromocytoma and hyperparathyroidism in multiple endocrine neoplasia type 2A: results of long-term follow-up. Surgery 1993;114(6):1070-1077.
5. Kocak S, Aydintug S, Ozbas S, et al. The importance of lifelong follow-up for patients with pheochromocytoma: report of a case. Surg Today 1996;26(10):839-841.
6. Tang SH, Chen A, Lee CT, et al. Remote recurrence of malignant pheochromocytoma 14 years after primary operation. J Urol 2003;169(1):269.
7. Lehnert H, Schulz C, Mundschenk J, et al. Clinical and endocrine diagnosis of pheochromocytoma. Zentbl Chir 1997;122(6):447-453.
8. Cheah WK, Clark OH, Horn JK, et al. Laparoscopic adrenalectomy for pheochromocytoma. World J Surg 2002;26(8):1048-1051.
9. Yanagi Y, Asaumi J, Hisatomi M, et al. Mandibular metastasis presenting as the initial manifestation of malignant pheochromocytoma. Eur J Radiol 2002;44(1):5-9.
10. Lenders JW, Pacak K, Eisenhofer G. New advances in the biochemical diagnosis of pheochromocytoma: moving beyond catecholamines. Ann N Y Acad Sci 2002;970:29-40.
11. Pacak K, Linehan WM, Eisenhofer G, et al. Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med 2001;134(4):315-329.
12. Eisenhofer G, Lenders JW, Pacak K. Choice of biochemical test for diagnosis of pheochromocytoma: validation of plasma metanephrines. Curr Hypertens Rep 2002;4(3):250-255.
13. Goldstein RE, O'Neill JA Jr, Holcomb GW III, et al. Clinical experience over 48 years with pheochromocytoma. Ann Surg 1999;229(6):755-764, discussion 764-766.
14. Prager G, Heinz-Peer G, Passler C, et al. Can dynamic gadolinium-enhanced magnetic resonance imaging with chemical shift studies predicts the status of adrenal masses? World J Surg 2002;26(8):958-964.
15. Honigschnabl S, Gallo S, Niederle B, et al. How accurate is MR imaging in characterization of adrenal masses: update of a long-term study. Eur J Radiol 2002;41(2):113-122.
16. Edwin B, Kazaryan AM, Mala T, et al. Laparoscopic and open surgery for pheochromocytoma. BMC Surg 2001;1(1):2.
17. Rabii R, Cicco A, Salomon L, et al. Laparoscopic excision of para-aortic lymphatic metastasis of malignant pheochromocytoma. Ann Urol 2001;35(2):81-83.
18. Mobius E, Nies C, Rothmund M. Surgical treatment of pheochromocytomas: laparoscopic or conventional? Surg Endosc 1999;13(1):35-39.
19. Hovevey-Sion D, Eisenhofer G, Kopin IJ, et al. Metabolic fate of injected radiolabelled dopamine, and 2-fluorodopamine in rats. Neuropharmacology 1990;29(10):881-887.
20. Nielsen JT, Nielsen BV, Rehling M. Location of adrenal medullary pheochromocytoma by I-123 metaiodobenzyl-guanidine SPECT. Clin Nucl Med 1996;21(9):695-699.
21. Fujita A, Hyodoh H, Kawamura Y, et al. Use of fusion images of 1-131 metaiodobenzylguanidine, SPECT, and magnetic resonance studies to identify a malignant pheochromocytoma. Clin Nucl Med 2000;25(6):440-442.
22. John H, Ziegler WH, Hauri D, et al. Pheochromocytomas: can malignant potential be predicted? Urology 1999;53(4):679-683.
23. Glodny B, Winde G, Herwig R, et al. Clinical differences between benign and malignant pheochromocytomas. Endocr J 2001;48(2):151-159.
24. Daly PA, Landsberg L. Phaeochromocytoma: diagnosis and management. Bailliere's Clin Endocrinol Metab 1992;6(1):143-166.
25. van der Harst E, Bruining HA, Jaap Bonjer H, et al. Proliferative index in phaeochromocytomas: does it predict the occurrence of metastases? J Pathol 2000;191(2):175-180.
26. Plouin PF, Chatellier G, Fofol I, et al. Tumor recurrence and hypertension persistence after successful pheochromocytoma operation. Hypertension 1997;29(5):1133-1139.
27. Grouzmann E, Gicquel C, Plouin PF, et al. Neuropeptide Y and neuron-specific enolase levels in benign and malignant pheochromocytomas. Cancer 1990;66(8):1833-1835.
28. Pang LC, Tsao KC. Flow cytometric DNA analysis for the determination of malignant potential in adrenal and extra-adrenal pheochromocytomas or paragangliomas. Arch Pathol Lab Med 1993;117(11):1142-1147.
29. Nativ O, Grant CS, Sheps SG, et al. The clinical significance of nuclear DNA ploidy pattern in 184 patients with pheochromocytoma. Cancer 1992;69(11):2683-2687.
30. Dannenberg H, Speel EJ, Zhao J, et al. Losses of chromosomes 1p and 3q are early genetic events in the development of sporadic pheochromocytomas. Am J Pathol 2000;157(2):353-359.
31. Yoshimoto T, Naruse M, Zeng Z, et al. The relatively high frequency of p53 gene mutations in multiple and malignant pheochromocytomas. J Endocrinol 1998;159(2):247-255.
32. De Krijger RR, van der Harst E, van der Ham F, et al. Prognostic value of p53, bcl-2, and c-erbB-2 protein expression in pheochromocytomas. J Pathol 1999;188(1):51-55.
33. Zielke A, Middeke M, Hoffmann S, et al. VEGF-mediated angiogenesis of human pheochromocytomas is associated to malignancy and inhibited by anti-VEGF antibodies in experimental tumors. Surgery 2002;132(6):1056-1063, discussion 1063.
34. Salmenkivi K, Arola J, Voutilainen R, et al. Inhibin/activin betaB-subunit expression in pheochromocytomas favors benign diagnosis. J Clin Endocrinol Metab 2001;86(5):2231-2235.
35. Bamberger CM, Else T, Bamberger AM, et al. Telomerase activity in benign and malignant adrenal tumors. Exp Clin Endocrinol Diabetes 1999;107(4):272-275.
36. Porpiglia F, Destefanis P, Bovio S, et al. Cortical-sparing laparoscopic adrenalectomy in a patient with multiple endocrine neoplasia type IIA. Horm Res 2002;57(5-6):197-199.
37. Baghai M, Thompson GB, Young WF Jr, et al. Pheochromocytomas and paragangliomas in von Hippel-Lindau disease: a role for laparoscopic and cortical-sparing surgery. Arch Surg 2002;137(6):682-688, discussion 688-689.
38. Perry RR, Keiser HR, Norton JA, et al. Surgical management of pheochromocytoma pheocliromocytoma with the use of metyrosine. Ann Surg 1990;212(5):621-628.
39. Duh QY. Evolving surgical management for patients with pheochromocytoma. J Clin Endocrinol Metab 2001;86(4):1477-1479.
40. Bonati L, Rubini P, Guareschi C. Diagnosis and treatment of pheochromocytoma. Minerva Chir 2000;55(5):333-340.
41. Tanaka M, Tokuda N, Koga H, et al. Laparoscopic adrenalectomy for pheochromocytoma: comparison with open adrenalectomy and comparison of laparoscopic surgery for pheochromocytoma versus other adrenal tumors. J Endourol 2000;14(5):427-431.
42. Ichikawa T, Mikami K, Suzuki H, et al. Laparoscopic adrenalectomy for pheochromocytoma. Biomed Pharmacother 2002;56(suppl 1):149s-153s.
43. Matsuda T, Murota T, Oguchi N, et al. Laparoscopic adrenalectomy for pheochromocytoma: a literature review. Biomed Pharmacother 2002;56(suppl 1):32s-138s.
44. Henry JF, Sebag F, Iacobone M, et al. Results of laparoscopic adrenalectomy for large and potentially malignant tumors. World J Surg 2002;26(8):1043-1047.
45. Walz MK, Peitgen K, Neumann HP, et al. Endoscopic treatment of solitary, bilateral, multiple, and recurrent pheochmmocytomas and paragangliomas. World J Surg 2002;26(8):1005-1012.
46. Gotoh M, Ono Y, Hattori R, et al. Laparoscopic adrenalectomy for pheochromocytoma: morbidity compared with adrenalectomy for tumors of other pathology. J Endourol 2002;16(4):245-249, discussion 249-250.
47. 131I-metaiodobenzylguanidine. Nucl Med Commun 1993;14(10):856-861.
48. 131I] metaiodobenzylguanidine: results from ten years of experience. J Nucl Biol Med 1991;35(4):269-276.
49. 131I] metaiodobenzylguanidine: a French multicenter study. J Nucl Biol Med 1991;35(4):284-287.
50. 131I-MIBG): A comprehensive review of 116 reported patients. J Endocrinol Invest 1997;20(11):648-658.
51. Kruijtzer CM, Beijnen JH, Swart M, et al. Successful treatment with paclitaxel of a patient with metastatic extra-adrenal pheochromocytoma (paraganglioma). A case report and review of the literature. Cancer Chemother Pharmacol 2000;45(5):428-431.
52. Tada K, Okuda Y, Yamashita K. Three cases of malignant pheochromocytoma treated with cyclophosphamide, vincristine, and dacarbazine combination chemotherapy and alpha-methyl-p-tyrosine to control hypercatecholaminemia. Horm Res 1998;49(6):295-297.
53. Steinsapir J, Carr AA, Prisant LM, et al. Metyrosine and pheochromocytoma. Arch Intern Med 1997;157(8):901-906.
54. Noshiro T, Honma H, Shimizu K, et al. Two cases of malignant pheochromocytoma treated with cyclophosphamide, vincristine, and dacarbazine in a combined chemotherapy. Endocr J 1996;43(3):279-284.
55. Averbuch SD, Steakley CS, Young RC, et al. Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann Intern Med 1988;109(4):267-273.
56. van der Harst E, de Herder WW, Bruining HA, et al. [(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in benign and malignant pheochromocytomas. J Clin Endocrinol Metab 2001;86(2):685-693.
57. Yoshida S, Hatori M, Noshiro T, et al. Twenty-six-years' survival with multiple bone metastasis of malignant pheochromocytoma. Arch Orthop Trauma Surg 2001;121(10):598-600.
58. Norton JA. Adrenal tumors. In: Devita VT, Hellman S, Rosenbery SA, eds. Cancer: Principles and Practice of Oncology. Philadelphia: Lippincott-Raven Publishers; 1997:1659-1677.
59. Kloos RT, Gross MD, Francis IR, et al. Incidentally discovered adrenal masses. Endocr Rev 1995;16(4):460-484.
60. Bemini GP, Miccoli P, Moretti A, et al. Sixty adrenal masses of large dimensions: hormonal and morphologic evaluation. Urology 1998;51(6):920-925.
61. Wooten MD, King DK. Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature. Cancer 1993;72(11):3145-3155.
62. Pommier RF, Brennan MF. An eleven-year experience with adrenocortical carcinoma. Surgery 1992;112(6):963-970, discussion 970-971.
63. Skogseid B, Rastad J, Gobl A, et al. Adrenal lesion in multiple endocrine neoplasia type 1. Surgery 1995;118(6):1077-1082.
64. Gortz B, Roth J, Speel EJ, et al. MENI gene mutation analysis of sporadic adrenocortical lesions. Int J Cancer 1999;80(3):373-379.
65. Satge D, Philippe E, Ruppe M, et al. Neonatal carcinoma. Review of the literature apropos of a case. Bull Cancer 1988;75(4):373-384.
66. Pivnick EK, Furman WL, Velagaleti GV, et al. Simultaneous adrenocortical carcinoma and ganglioneuroblastoma in a child with Turner syndrome and germline p53 mutation. J Med Genet 1998;35(4):328-332.
67. Bornstein SR, Stratakis CA, Chrousos GP. Adrenocortical tumors: recent advances in basic concepts and clinical management. Ann Intern Med 1999;130(9):759-771.
68. Kirschner LS. Signaling pathways in adrenocortical cancer. Ann N Y Acad Sci 2002;968:222-239.
69. Reincke M, Mora P, Beuschlein F, et al. Deletion of the adrenocorticotropin receptor gene in human adrenocortical tumors: implications for tumorigenesis. J Clin Endocrinol Metab 1997;82(9):3054-3058,
70. Komminoth P, Roth J, Schroder S, et al. Overlapping expression of immunohistochemical markers and synaptophysin mRNA in pheochromocytomas and adrenocortical carcinomas. Implications for the differential diagnosis of adrenal gland tumors. Lab Invest 1995;72(4):424-431.
71. Sasano H, Suzuki T, Shizawa S, et al. Transforming growth factor alpha, epidermal growth factor, and epidermal growth factor receptor expression in normal and diseased human adrenal cortex by immunohistochemistry and in situ hybridization. Mod Path 1994;7(7):741-746.
72. Edgren M, Erikson B, Wilander E, et al. Biological characteristics of adrenalcortical carcinoma: a study of p53, IGF, EGF-r, Ki-67 and PCNA in 17 adrenocortical carcinomas. Anticancer Res 1997;17(2B):1303-1309.
73. Kendrick ML, Lloyd R, Erickson L, et al. Adrenocortical carcinoma: surgical progress or status quo? Arch Surg 2001;136(5):543-549.
74. Icard P, Goudet P, Charpenay C, et al. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J Surg 2001;25(7):891-897.
75. Stratakis CA, Chrousos GP. Endocrine tumors. In: Passo PA, Poplack DG, eds. Principles and Practice of Peadiatric Oncology. Philadelphia: Lippincott-Raven Publishers; 1997:947-976.
76. Kasperlik-Zaluska AA, Migdalska BM, Zgliczynski S, et al. Adrenocortical carcinoma. A clinical study and treatment results of 52 patients. Cancer 1995;75(10):2587-2591.
77. Barnett CC Jr, Varma DG, El-Naggar AK, et al. Limitations of size as a criterion in the evaluation of adrenal tumors. Surgery 2000;128(6):973-982, discussion 982-983.
78. Hussain S, Belldegrun A, Seltzer SE, et al. Differentiation of malignant from benign adrenal masses: predictive indices on computed tomography. AJR Am J Roentgenol 1985;144(1):61-65.
79. Doppman JL, Reinig JW, Dwyer AJ, et al. Differentiation of adrenal masses by magnetic resonance imaging. Surgery 1987;102(6):1018-1026.
80. Boland GW, Lee MJ. Magnetic resonance imaging of the adrenal gland. Crit Rev Diagn Imaging 1995;36(2):115-174.
81. Arteaga E, Biglieri EG, Kater CE, et al. Aldosterone-producing adrenocortical carcinoma. Preoperative recognition and course in three cases. Ann Intern Med 1984;101(3):316-321.
82. Korobkin M, Lombardi TJ, Aisen AM, et al. Characterization of adrenal masses with chemical shift and gadolinium-enhanced MR imaging. Radiology 1995;197(2):411-418.
83. Stojadinovic A, Ghossein RA, Hoos A, et al. Adrenocortical carcinoma: clinical, morphologic, and molecular characterization. J Clin Oncol 2002;20(4):941-950.
84. Macfarlane DA. Cancer of the adrenal cortex: the natural history, prognosis and treatment in a study of fifty-five cases. Ann R Coll Surg Engl 1958;23:155.
85. Sullivan M, Boileau M, Hodges CV. Adrenal cortical carcinoma. J Urol 1978;120(6):660-665.
86. Crucitti F, Bellantone R, Ferrante A, et al. The Italian Registry for Adrenal Cortical Carcinoma: analysis of a multiinstitutional series of 129 patients. The ACC Italian Registry Study Group. Surgery 1996;119(2):161-170.
87. Percarpio B, Knowlton A.H. Radiation therapy of adrenal cortical carcinoma. Acta Radiol Ther Phys Biol 1976;15:288.
88. Markoe AM, Serber W, Micaily B, et al. Radiation therapy for adjunctive treatment of adrenal cortical carcinoma. Am J Clin Oncol 1991;14(2):170-174.
89. Luton JP, Cerdas S, Billaud L, et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 1990;322(17):1195-1201.
90. Haak HR, Hennans J, van de Velde CJ, et al. Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer 1994;69(5):947-951.
91. Abraham J, Bakke S, Rutt A, et al. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etopo side with daily mitotane as a P-glycoprotein antagonist. Cancer 2002;94(9):2333-2343.
92. Angeli A, Osella G, Ali A, et al. Adrenal incidentaloma: an overview of clinical and epidemiological data from the National Italian Study Group. Horm Res 1997;47(4-6):279-283.
93. Proye CAG, Pattou FN. Adrenocortical carcinoma: nonfunctioning and functioning. In: Clark OH, Duh QY, eds. Textbook of Endocrine Surgery. Philadelphia: Saunders; 1997:490-496.
94. Porte HL, Roumilhac D, Graziana JP, et al. Adrenalectomy for a solitary adrenal metastasis from lung cancer. Ann Thorac Surg 1998;65(2):331-335.
95. Katayama A, Mafune K, Makuuchi M. Adrenalectomy for solitary adrenal metastasis from colorectal carcinoma. Jpn J Clin Oncol 2000;30(9):414-416.
96. Tsuji Y, Yasuhuku M, Haryu T, et al. Laparoscopic adrenalectomy for solitary metachronous adrenal metastasis from lung cancer: report of a case. Surg Today 1999;29(12):1277-1279.
97. Elashry OM, Clayman RV, Soble JJ, et al. Laparoscopic adrenalectomy for solitary metachronous contralateral adrenal metastasis from renal cell carcinoma. J Urol 1997;157(4):1217-1222.
98. Kebebew E, Siperstein AE, Clark OH, et al. Results of laparoscopic adrenalectomy for suspected and unsuspected malignant adrenal neoplasms. Arch Surg 2002;137(8):948-951, discussion 952-923.